Benzinga | Jan 10, 2022 07:41AM EST

Acadia Pharmaceuticals And Stoke Therapeutics Announce Collaboration To Pursue Multiple RNA-based Treatments For Severe And Rare Genetic Neurodevelopmental Diseases

-- Establishes co-development and co-commercialization agreement for Stoke's SYNGAP1 preclinical program

-- Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed neurodevelopmental target

-- Combines Stoke's TANGO research platform with Acadia's expertise in neurology drug development and commercialization

-- Stoke receives a $60 million upfront payment and potential milestone payments of up to $907 million and royalties on future sales